Glaukos (GKOS)
(Delayed Data from NYSE)
$133.89 USD
+1.30 (0.98%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $133.95 +0.06 (0.04%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$133.89 USD
+1.30 (0.98%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $133.95 +0.06 (0.04%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Zacks News
Glaukos (GKOS) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Glaukos (GKOS) witnessed a contraction in gross margin but year-over-year revenue surge in Q1.
Glaukos (GKOS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of -25.71% and -0.10%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Glaukos (GKOS) Down 45.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Glaukos (GKOS) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Glaukos (GKOS) fourth-quarter results benefit from revenue growth. However, rise in operating expenses remains a concern.
What's in the Offing for LabCorp's (LH) Earnings in Q4?
by Zacks Equity Research
With near-term visibility seeming bleak at the moment, we anticipate PAMA to once again dent LabCorp's (LH) fourth-quarter top line.
What's in the Cards for DaVita (DVA) This Earnings Season?
by Zacks Equity Research
DaVita (DVA) expects to have gained from calcimimetics in the fourth quarter.
BD Life Sciences to Aid Becton, Dickinson (BDX) Q1 Earnings
by Zacks Equity Research
BD's (BDX) core Life Sciences arm is expected to have driven first-quarter performance.
Why Is Glaukos (GKOS) Up 1.2% Since Last Earnings Report?
by Zacks Equity Research
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Glaukos (GKOS) Q3 Loss Narrower Than Expected, '19 View Up
by Zacks Equity Research
Glaukos' (GKOS) Q3 revenues surge year over year. Also, the company raises 2019 revenue guidance.
Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of 41.18% and 3.50%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Glaukos (GKOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Glaukos (GKOS) Up 2.3% Since Last Earnings Report?
by Zacks Equity Research
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Glaukos (GKOS) Q2 Loss Wider Than Estimates, '19 View Raised
by Zacks Equity Research
Glaukos (GKOS) raises 2019 revenues view; optimistic about Avedro buyout.
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of -10.00% and 4.30%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Glaukos (GKOS) Down 2.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of 66.67% and 7.77%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Glaukos (GKOS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaukos (GKOS) Banks on Solid Pipeline Amid Stiff Competition
by Zacks Equity Research
Glaukos' (GKOS) strong pipeline is indicative of brighter prospects ahead. However, cutthroat competition in the medical-device industry is worrisome.
Earnings Preview: Glaukos (GKOS) Q4 Earnings Expected to Decline
by Zacks Equity Research
Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of -35.71% and 8.94%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Glaukos (GKOS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaukos (GKOS) Jumps: Stock Rises 7.2%
by Zacks Equity Research
Glaukos (GKOS) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of -15.38% and 5.85%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Is SPDR S&P Health Care Equipment ETF (XHE) a Hot ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Weakness Seen in Glaukos (GKOS) Estimates: Should You Stay Away?
by Zacks Equity Research
Glaukos (GKOS) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.